<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800917</url>
  </required_header>
  <id_info>
    <org_study_id>BEV-CCI-779-GBM-02</org_study_id>
    <secondary_id>Eudract no.: 2008-003679-40</secondary_id>
    <nct_id>NCT00800917</nct_id>
  </id_info>
  <brief_title>A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>A Phase II Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is an investigator initiated, open label phase II study, where patient with&#xD;
      recurrent primary GBM will be considered for the study. Only patients with recurrence after&#xD;
      Temozolomide and VEGF-directed therapy with Bevacizumab will be considered for the study.&#xD;
      Patients will receive temsirolimus 25 mg IV over 30-60 minutes on days 1, 8, 15 and 22 and&#xD;
      bevacizumab 10 mg/kg IV over 30-90 minutes on day 8 and 22. Treatment repeats every 28 days&#xD;
      for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. A&#xD;
      safety analysis will be performed when the first 10 patients have received minimum 4 cycles&#xD;
      (8 weeks). The study will then be stopped:&#xD;
&#xD;
      If DLT is observed in &gt; 2/10 patients, Occurrence of any serious adverse events not described&#xD;
      in the SPC of each agents, If partial remission is not observed in at least 1/10 patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival in months</measure>
    <time_frame>From start of treatment to death or progression</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>every 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate</measure>
    <time_frame>every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre- vs post-treatment measurements of biomarkers and vascular system/immune system parameters</measure>
    <time_frame>weekly for the first 4 weeks, then every 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation with biomarkers</measure>
    <time_frame>at the end of the study</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>25 mg weekly IV</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>10 mg/kg every 2 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histological verification of primary GBM and failure after radiotherapy and&#xD;
             temozolomide (TMZ)&#xD;
&#xD;
          -  Previously treated with VEGF-directed therapy with bevacizumab&#xD;
&#xD;
          -  Previously received radiotherapy and temozolomide&#xD;
&#xD;
          -  More than 4 weeks since any of the following prior treatments: chemotherapy (6 weeks&#xD;
             for nitrosoureas or mitomycin C)&#xD;
&#xD;
          -  Radiotherapy to nontarget lesions or lesions that are not to be biopsied VEGF-directed&#xD;
             therapy (including bevacizumab)&#xD;
&#xD;
          -  Investigational agents&#xD;
&#xD;
          -  More than 6 months since prior major surgery or open biopsy and recovered (only 6&#xD;
             weeks required if operation is for recurrent GBM)&#xD;
&#xD;
          -  No concurrent medications or substances known to affect or with the potential to&#xD;
             affect the activity or pharmacokinetics of the following:&#xD;
&#xD;
               -  Temsirolimus&#xD;
&#xD;
               -  Bevacizumab&#xD;
&#xD;
               -  CYP450 isoenzymes&#xD;
&#xD;
               -  ECOG performance status 0-1&#xD;
&#xD;
               -  WBC ≥ 3,000 mm³&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
               -  Bilirubin and phosphate normal&#xD;
&#xD;
               -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
               -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
               -  Urine protein: creatinine ratio &lt; 1.0 OR 24-hour urine protein &lt; 1,000 mg&#xD;
&#xD;
               -  Fasting cholesterol &lt; 350 mg/dL (cholesterol medications are allowed)&#xD;
&#xD;
               -  Fasting triglycerides &lt; 400 mg/dL&#xD;
&#xD;
               -  PT INR ≤ 1.5&#xD;
&#xD;
               -  Hematocrit &lt; 41% (for males) or &lt; 38% (for females)&#xD;
&#xD;
               -  Fertile females must use an approved contraceptive (p-pills, IUD, depot injection&#xD;
                  of gestagen, subdermal implantation, hormonal vaginal ring or transdermal depot&#xD;
                  plaster), throughout the study and 3 months after discontinuation of study drugs.&#xD;
                  Fertile men must use dobbelt barrier method (preservative with sperm inhibiting&#xD;
                  creme) or female partner uses the above mentioned contraceptive.&#xD;
&#xD;
          -  Fertile males must use preservatives.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant cardiovascular disease, including the following:&#xD;
&#xD;
          -  Cerebrovascular accident within the past 6 months&#xD;
&#xD;
          -  Transient ischemic attack within the past 6 months&#xD;
&#xD;
          -  Myocardial ischemia within the past 6 months&#xD;
&#xD;
          -  Myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Other thromboembolic event within the past 6 months&#xD;
&#xD;
          -  Unstable angina within the past 6 months&#xD;
&#xD;
          -  Uncontrolled hypertension (i.e., hypertension despite maximal therapy)&#xD;
&#xD;
          -  New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  Ongoing or active infection&#xD;
&#xD;
          -  One of the following within the past 6 months&#xD;
&#xD;
          -  Abdominal fistula&#xD;
&#xD;
          -  Gastrointestinal perforation&#xD;
&#xD;
          -  Intra-abdominal abscess&#xD;
&#xD;
          -  Serious or nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Psychiatric illness or social situations that would preclude study compliance&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Hemoglobin A1c &gt; 7%&#xD;
&#xD;
          -  Concurrent non-study related surgical procedures&#xD;
&#xD;
          -  Concurrent treatment with CYP3A4 inducers or inhibitors&#xD;
&#xD;
          -  Other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  Significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  History of allergic reactions to compounds of similar chemical or biological&#xD;
             composition to temsirolimus or bevacizumab&#xD;
&#xD;
          -  Hypersensitivity to Chinese hamster ovary cell products or other recombinant human&#xD;
             antibodies (e.g., infliximab)&#xD;
&#xD;
          -  Pregnancy or nursing&#xD;
&#xD;
          -  Patients previously intolerant to bevacizumab&#xD;
&#xD;
          -  Anticoagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <last_update_submitted>June 1, 2010</last_update_submitted>
  <last_update_submitted_qc>June 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ulrik Lassen, MD, PH.D.</name_title>
    <organization>Rigshospitalet</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

